Table 3.
Performance of the HCII and PCR to detect low-grade squamous intraepithelial lesions (lsils) and high-grade squamous intraepithelial lesions (hsils) in screening and diagnostic groups.
| HPV Prevalence (%) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | |
|---|---|---|---|---|---|
| LSILs | |||||
| HCII | |||||
| Screening group | 1.2 | 16.8 (10.5–25.5) | 88.7 (86.2–90.8) | 16.7 (10.4–25.3) | 88.8 (86.4–90.9) |
| Diagnostic group | 10.7 | 41.9 (34.9–49.2) | 46.3 (42.1–50.6) | 21.1 (17.2–25.6) | 70.0 (65.0–74.5) |
| PCR | |||||
| Screening group | 7.62 | 64.5 (54.6–73.3) | 32.8 (29.6–36.2) | 11.4 (9.0–14.3) | 87.3 (82.9–90.7) |
| Diagnostic group | 21.7 | 84.8 (78.7–89.4) | 14.4 (11.6–17.6) | 25.3 (22.1–29.0) | 73.4 (63.9–81.2) |
| HSILs | |||||
| HCII | |||||
| Screening group | 1.6 | 78.6 (48.8–94.3) | 89.1 (86.8–91.0) | 10.2 (5.4–17.9) | 99.6 (98.8–99.9) |
| Diagnostic group | 27.7 | 94.6 (90.4–97.2) | 66.2 (62.0–70.1) | 51.7 (46.6–56.8) | 97.0 (94.6–98.4) |
| PCR | |||||
| Screening group | 1.6 | 78.6 (48.8–94.3) | 33.3 (30.2–36.5) | 1.8 (0.96–3.3) | 99.0 (96.9–99.7) |
| Diagnostic group | 27.7 | 94.2 (89.9–96.8) | 17.9 (14.8–21.6) | 30.5 (27.0–34.3) | 89.0 (81.2–93.9) |
Abbreviations: LSILs, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions; HCII, hybrid capture II; PCR, polymerase chain reaction; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.